Umber Saeed and Usman Choudhary
Dow University of Health & Sciences, Pakistan
Posters & Accepted Abstracts: Oncol Cancer Case Rep
Breast cancer is one of the leading causes of death worldwide. In Pakistan, prevalence of this ailment is highest amongst all types of cancer i.e. 38.5%. Major clinical setback is drug resistance in breast cancer. Metabolomics is an emerging field that utilizes information of cellular biochemistry for the early detection, diagnosis and establishment of predictive biomarkers of breast cancer. This review highlights potential metabolomics applications to clinical pharmacology. The methodology is based on inclusion exclusion criteria. Literature survey and questionnaire were included while clinical trial was excluded. This report provides a review of 12 articles out of few were excluded. The objective was to explore 1) early breast cancer detection, 2) increasing life expectancy of cancer patients and 3) mechanisms for breast cancer drug resistance. According to the survey, the average response rate of a cancer drug is the lowest at 21%, suggesting that 79% of patients with cancer are over-dosed. While according to an international study, 40%â??50% of breast tumors will display acquired resistance. When specific therapies are chosen on the basis of a patientâ??s metabolomics profile, it will give rise to customized medicine and personalized tailored treatment. Using high-throughput information using metabolomics to clinical diagnosis and treatment can help accelerate the patient safety, quality of life and survival rate by identifying pathways involved in drug resistance. Metabolomics is future of anti-cancer pharmacology; following â??the right drug for the right patient at the right timeâ? can offer safety, quality and effectiveness of anti-cancer treatment.